Shen CZ, Carol H, Feng R, Hill A, Lopes Almeida Gomes L, Hejazi EZ, Werth VP, Shaw KS. Risk of interstitial lung disease in adult patients with dermatomyositis treated with methotrexate: A retrospective analysis of a prospective cohort , J Am Acad Dermatol, 92(5): 2025,1098-1100
Cepica TB, Xie L, Faden DF, Stone CJ, Feng R, Werth VP, Chong BF. Smoking status is a negative predictor of six-month cutaneous lupus activity trends: A prospective cohort study , J Am Acad Dermatol, 92(4): 2025,912-914
Zanframundo G, Dourado E, Bauer-Ventura I, Faghihi-Kashani S, Yoshida A, Loganathan A, Rivero-Gallegos D, Lim D, Bozán F, Sambataro G, Bae SS, Yamano Y, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Hansen P, Rozza D, Scirè CA, Sakellariou G, Kaneko Y, Triantafyllias K, Castañeda S, Alberti ML, Merino MGG, Fiehn C, Molad Y, Govoni M, Nakashima R, Alpsoy E, Giannini M, Chinoy H, Gallay L, Ebstein E, Campagne J, Saraiva AP, Conticini E, Sebastiani GD, Nuño-Nuño L, Scarpato S, Schiopu E, Parker M, Limonta M; CLASS project participating investigators; Cavagna L, Aggarwal R. The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project , Ann Rheum Dis, 4967(25): 2025
Werth VP, Furie RA, Romero-Diaz J, Navarra S, Kalunian K, van Vollenhoven RF, Nyberg F, Kaffenberger BH, Sheikh SZ, Radunovic G, Huang X, Carroll H, Naik H, Gaudreault F, Meyers A, Musselli C, Franchimont N, Barbey C. Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary , Immunotherapy, 17(3): 2025,161-173
Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA. Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial , Lancet, 405(10473): 2025,137-146
Xie L, Faden DF, Stone CJ, Lopes Almeida Gomes L, Feng R, Werth VP. Subtype and Racial Erythema Variation for Cutaneous Lupus Trials , JAMA Dermatol, 161(1): 2025,67-74
Khosravi-Hafshejani T, Werth VP. Serum IFNα as a Biomarker for Cutaneous Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application , J Invest Dermatol: 2025
Hile GA, Werth VP. Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics , Arthritis Rheumatol, 77(1): 2025,1-11
Ogawa-Momohara M, Vazquez T, Chin F, Sharma M, Dan J, Sprow G, Werth VP. Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth, B-Cell-Directed Immunoprofile , J Invest Dermatol, 145(1): 2025,190-193
Pandya R, Dan J, Kleitsch J, Lim D, White B, Werth VP. Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials , JID Innov, 5(2): 2024,100337
